Role of Cytochrome P4502B6 in Methadone Metabolism and Clearance
Year: 2013
Type: article
Study design: Clinical Trial
Abstract: Methadone N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4. This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days. A preliminary clinical investigation with the CYP3A4/5 substrate probe alfentanil established that ticlopidine did not inhibit intestinal or hepatic CYP3A4/5. Subjects received intravenous plus oral (deuterium-labeled) racemic methadone before and after ticlopidine. Ticlopidine significantly and stereoselectively (S > R) inhibited methadone N-demethylation, decreasing plasma metabolite/methadone area under the curve ratios and metabolite formation clearances. Ticlopidine also significantly increased the dose-adjusted plasma area under the curve for R- and S-methadone by 20% and 60%, respectively, after both intravenous and oral dosing. CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition.
DOI: 10.1002/jcph.1
Authors: Evan D. Kharasch, Kristi Stubbert
Institution: Washington University in St. Louis
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: green
Awards: METHADONE AND HIV DRUG INTERACTIONS, Opioids in Cancer Pain & Drug Abuse: Optimizing Therapy, G5394216113, Washington University Institute of Clinical and Translational Sciences, Novel noninvasive assessment of cytochrome P450 activity, Washington University Institute of Clinical and Translational Sciences (UL1)
OpenAlex ID: W1891090353
